KYBELLA®

KYBELLA® (deoxycholic acid) injection is the first and only FDA-approved injectable treatment that is used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called, "double chin". It is not known if KYBELLA® is safe and effective in children less than 18 years of age. It is not known if KYBELLA® is safe and effective for use outside of the submental area. Between one to 4 treatments may be needed for your desired results.

Each Kybella® treatment for reduction of double chin or submental fat takes less than 20 minutes.

There is minimal discomfort during the treatment and mild swelling for 2-3 days following the.


KYBELLA® may be right for you if:

  • You're bothered (unhappy, self-conscious, embarrassed) by fat under the chin, also known as submental fullness
  • You feel the condition makes you look older or heavier than you actually are.
  • You don't want to have surgery
  • You eat well and exercise, but submental fullness does not go away
  • Treatment requires minimal downtime or recovery; it's often called a lunchtime procedure. You'll be able to go about your normal routine immediately after you leave your specialist's office.


Jason, 36 years
Total Treatments: 6
After Image After (Day 7)
Before Image Before

Actual patients. Unretouched photos taken before treatment and after final treatment. Individual results may vary.

Multiple injections under the chin per treatment; up to 6 treatments spaced at least 1 month apart. 59% of patients received 6 KYBELLA® treatments in clinical studies. Treatment is tailored to the amount of fat under the chin and aesthetic goals.

68.2% of patients treated with KYBELLA® in 2 clinical studies had some/moderately better improvement, compared with 20.5% of patients treated with placebo (70% vs 18.6% in Study 1, 66.5% vs 22.2% in Study 2).

16% of patients treated with KYBELLA® in 2 clinical studies had significant/a great deal better improvement, compared with 2% of patients treated with placebo (13.4% vs less than 0% in Study 1, 18.6% vs 3% in Study 2).